Permeability of antipyrine and creatinine and viability characteristics during in vitro perfusions
Arithmetic means and 95% confidence intervals (in parentheses) are given.
| Protocol | n | Glucose Consumption | Lactate Production | Antipyrine Permeability | Creatinine Permeability |
|---|---|---|---|---|---|
| μmol × min-1× g-1 | μmol × min-1× g-1 | ml × min-1× g-1 | ml × min-1× g-1 | ||
| Study (maternofetal versus fetomaternal permeability) | |||||
| Maternofetal | 8 | 0.21 (0.14, 0.28) | 0.45 (0.30, 0.60) | 0.10 (0.07, 0.12) | 0.015 (0.011, 0.018) |
| Fetomaternal | 8 | 0.21 (0.13, 0.28) | 0.39 (0.29, 0.49) | 0.07 (0.04, 0.10) | 0.020 (0.014, 0.026) |
| Study (maternofetal permeability in presence of inhibitors) | |||||
| Control | 6 | 0.32 (0.03, 0.62) | 0.59 (0.05, 1.12) | 0.09 (0.003, 0.18) | 0.038 (0.001, 0.075) |
| PSC833 | 6 | 0.32 (0.10, 0.54) | 0.66 (0.04, 1.27) | 0.11 (0.05, 0.17) | 0.042 (0.010, 0.075) |
| Control | 6 | 0.29 (0.15, 0.43) | 0.55 (0.30, 0.80) | 0.09 (0.04, 0.15) | 0.021 (0.016, 0.026) |
| Probenecid | 6 | 0.36 (0.12, 0.61) | 0.79 (0.32, 1.27) | 0.07 (0.04, 0.11) | 0.019 (0.014, 0.024) |
| Control | 6 | 0.27 (0.17, 0.37) | 0.54 (0.20, 0.87) | 0.10 (0.05, 0.15) | 0.025 (0.018, 0.031) |
| Verapamil | 6 | 0.26 (0.18, 0.34) | 0.48 (0.28, 0.68) | 0.10 (0.06, 0.13) | 0.025 (0.021, 0.028) |